Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

484

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Breast Cancer
Interventions
DRUG

RP-6306

Dose and schedule will be assigned at enrolment

DRUG

Gemcitabine

Dose and schedule will be assigned at enrolment

OTHER

Observation

Monitoring arm

DRUG

Niraparib

Dose and schedule will be assigned at enrolment

DRUG

Fulvestrant

Dose and schedule will be assigned at enrolment

DRUG

RP-3500

Dose and schedule will be assigned at enrolment

Trial Locations (10)

T2N 5G2

RECRUITING

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

V1Y 5L3

RECRUITING

BCCA - Kelowna, Kelowna

V5Z 4E6

RECRUITING

BCCA - Vancouver, Vancouver

B3H 1V7

RECRUITING

QEII Health Sciences Centre, Halifax

L8V 5C2

RECRUITING

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

RECRUITING

Kingston Health Sciences Centre, Kingston

K1H 8L6

RECRUITING

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

SUSPENDED

Odette Cancer Centre, Toronto

M5G 2M9

RECRUITING

University Health Network, Toronto

H3T 1E2

RECRUITING

The Jewish General Hospital, Montreal

All Listed Sponsors
lead

Canadian Cancer Trials Group

NETWORK